Skip to main content
OpenTrials
Completed

NCT Number: NCT00209950

A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia

To evaluate the safety and tolerability of gaboxadol in primary insomnia

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Primary Insomnia Dyssomnias Mental Disorders Nervous System Diseases Sleep Disorders, Intrinsic Sleep Initiation and Maintenance Disorders Sleep Wake Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Non-US study, principal location:

Regensburg, Germany

About this study

To evaluate long-term safety of gaboxadol in healthy adults.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients with a diagnosis of primary insomnia

Treatment and study plan

Gaboxadol

Drug

Primary outcomes

  1. Safety

  2. Tolerability

Sponsors and collaborators

Lead sponsor

H. Lundbeck A/S

Industry

Registry information

Official study title

A Prospective Open-Label Extension Study (to Study 99784) of Gaboxadol in Primary Insomnia

Important dates

Study start
2004
Study completion
2005
First posted
Sep 21, 2005
Registry last updated
Mar 30, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.